Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.
Dr. Jenna DiRito talks about why human organs may represent the “missing chapter” in our understanding of disease, and how this approach is already changing conversations with investors and regulators.
Dr. Jenna DiRito talks about why human organs may represent the “missing chapter” in our understanding of disease, and how this approach is already changing conversations with investors and regulators.